|
市場調查報告書
複方製劑動向
SPECIAL REPORT: Getting Maximum Benefit from Combination Products
|
本報告已在2011年12月21日停止出版。
複方製劑成為今日藥品產業中最大的產品線。許多企業雖然為了延長專利期限以獲得最大收益，都在產品生命週期的後半採用複方製劑，但仍有必要因應市場尚未被滿足的需求進行產品開發。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. 總公司：Massachusetts State），針對複方製劑動向進行調查分析，並系統整理調查結果後出版報告書"SPECIAL REPORT: Getting Maximum Benefit from Combination Products"。
本報告書內容包括：複方製劑的動向及尚未被滿足的需求、新興複方製劑、擁有暢銷藥品的企業概要、課題、專家評論等。內容綱要摘記如下：
實施概要
複方製劑的範圍
- 規範趨勢
- 最新的生物藥劑及設備之認可
- 藥劑及設備的整合
複方製劑的策略性運用
固定用量複方製劑最近在市場中的成功範例
- 固定用量複方製劑暢銷藥
- GlaxoSmithKline的Advair/Seretide
- AstraZeneca的Symbicort及Boehringer Ingelheim的Combivent
- Merck/Schering-Plough的Vytorin/Inergy
- Novartis的Lotrel
- 針對HIV/AIDS的複合暢銷藥
- 抗菌性複合暢銷藥
- 避孕用複合暢銷藥
- 對複方製劑市場的關注
- 品牌藥品製造商
- 非專利藥品製造商
值得關注的動向
- 更加及時的複方製劑開發
- 固定用量複方製劑相關企業間合作
- Bristol-Myers Squibb及Gilead Sciences
- AstraZeneca及Abbott
- Schering-Plough及Novartis
- 數種藥物製成的複方製劑
- 在日本複方製劑的廣泛知名度
- 新興企業在新的適用症狀中應用複方製劑
- CombinatoRx
- Orexigen
- Vicus Therapeutics
生命週期管理及市場動向
- 分散的糖尿病市場
- 繼COX-2抑制劑之後NSAID複方製劑的復興
- AstraZeneca/Pozen
- GlaxoSmithKline/Pozen
- 研發中的固定用量複方製劑
- 心血管疾病
- Pfizer的Torcetrapib/Lipitor複方製劑
- Novartis的Exforge
- Merck/Schering-Plough的Lipitor及Zetia
- 第一三共股份有限公司的CS-8663
- Merck的MK-0524A及MK-0524B
- Abbott的Simcor
- 相互適用的複方製劑治療
- 呼吸器官疾病
- Schering-Plough及Novartis的LABA和腎上腺皮質類固醇的複方製劑
- Nycomed及Sanofi-Aventis的Formoterol和Alvesco的複方製劑
- GlaxoSmithKline及Theravance的針對COPD的有潛力的固定用量複方製劑
未來發展前景
附錄：2006年治療領域別全球最暢銷的複方製劑
Abstract
Introduction
Combination products are a lifeline in today' s pharmaceutical industry, but
not all are created equal. Many companies use combinations late in the product
life cycle to extend patent life or to maximize revenues, but more-successful
combination product development addresses a market' s unmet need. Therefore,
not all potential combination products will have equal value. We asked
Decision Resources analysts to share their insights on combination products in
various disease markets and integrated these insights into our analysis of the
combination product market in this Spectrum Special Report.
Get the Answers You Need to Shape Your Strategy
- Several fi xed-dose combinations were blockbusters in 2006 while others
languished. Why do combination products fare well in some markets and not in
others? Why do similar products for similar indications fare very differently
in the market?
- Successful combinations are sometimes a result of a single company
combining its blockbuster agents, but several intercompany collaborations on
combination products have proved very successful. Which partnerships have been
most successful and why? Which markets are best suited to further intercompany
development?
- Combination products are becoming increasingly useful in product
life-cycle management. Which combination products are in development? What do
the experts think of their chances for success?
Scope
- Trends in Combination Products: Synergistic partnerships that tap unmet
needs in disease markets.
- Emerging Combinations in Select Markets: Cardiovascular, respiratory,
diabetes, pain.
- Select Companies with Fixed Combination Blockbusters: Abbott, AstraZeneca,
Boehringer Ingelheim, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck,
Novartis, Schering-Plough.
- Challenges: Incorporating the untapped opportunity of biologics into
combination product development.
- Expert Commentaries: Insights from Decision Resources analysts,
consultants, and directors.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- The Breadth and Scope of Combination Products
- From a Regulatory Perspective
- Recent Biologic and Device Approvals
- Drug-and-Device Combinations Going Strong
- Strategic Use of Combination Products
- Recent Market Success of Fixed-Dose Combinations
- Fixed-Dose Combination Blockbusters
- GlaxoSmithKline' s Advair/Seretide
- AstraZeneca' s Symbicort and Boehringer Ingelheim' s Combivent
- Merck/Schering-Plough' s Vytorin/Inegy
- Novartis' s Lotrel
- HIV/AIDS Combination Blockbusters
- Antibacterial Combination Blockbusters
- Combination Blockbusters in a Contraceptive Franchise
- Signifi cant Interest in Combination-Drug Markets
- Brand Pharmaceutical Companies
- Generics Pharmaceutical Companies
- Notable Trends
- More Timely Development of Combinations
- Intercompany Collaborations on Fixed-Dose Combinations
- Bristol-Myers Squibb and Gilead Sciences
- AstraZeneca and Abbott
- Schering-Plough and Novartis
- Multiple Combinations
- Greater Acceptance of Combination Products in Japan
- Start-Up Companies Dedicated to Combinations in Novel Indications
- CombinatoRx
- Orexigen
- Vicus Therapeutics
- Life-Cycle Management and Market Dynamics
- Fragmented Diabetes Markets
- Thiazolidinedione Franchises
- Renaissance in NSAID Combinations Following COX-2 Inhibitor Troubles
- AstraZeneca/Pozen
- GlaxoSmithKline/Pozen
- Fixed-Dose Combination Drugs in Development
- Cardiovascular Combinations
- Pfi zer' s Torcetrapib/Lipitor Combination
- Novartis' s Exforge
- Merck/Schering-Plough' s Lipitor and Zetia
- Daiichi Sankyo' s CS-8663
- Merck' s MK-0524A and MK-0524B
- Abbott' s Simcor
- Cross-Indication Combination Therapies
- Respiratory Combinations
- Schering-Plough and Novartis LABA and Corticosteroid Combinations
- Nycomed and Sanofi -Aventis' s Formoterol and Alvesco Combination
- GlaxoSmithKline and Theravance' s Promising Fixed-Dose Combinations for
COPD
- Outlook
- Appendix-World' s Best-Selling Combination Products by Therapeutic
Category, 2006
Expert Commentary
- Expert Commentary: Fixed-Dose Combinations of Antiretroviral Drugs in HIV
Therapy Regimens
- Expert Commentary: Patent Expirations and the Availability of
Generic-and-Generic Combinations Loom Heavily Over Type 2 Diabetes Markets
- Expert Commentary: Choosing the Right Drugs for the Combination Is of
Paramount Importance
- Expert Commentary: Opportunities for Respiratory Fixed-Dose Combinations
Tables
- 1. Start-Up Companies Dedicated to Drug Repurposing
- 2. Summary Table: Key Opportunities and Challenges in Combination Product
Development According to Decision Resources Experts
Figures
- 1. Best-Selling Fixed Combination Blockbusters Worldwide, 2006
- 2. Best-Selling Combination Products by Therapeutic Category, 2006
- 3. Big Pharma' s Degree of Interest in Combination Products, 2006
- 4. Life-Cycle Management Through Fixed-Dose Combinations in Diabetes
- 2a. Fragmented Market Dynamics in Diabetes, 2000-2006
- 3a. Vytorin Enjoys Tremendous Success While Caduet Struggles
|
